M. D. de Jonge

发表

Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors

E. Wiemer, N. Naus, R. Mathijssen, 2014, Clinical Cancer Research.

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.

E. Wiemer, J. Verweij, P. de Bruijn, 2009, Journal of Pharmaceutical and Biomedical Analysis.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

S. Sleijfer, P. V. van Diest, E. Cuppen, 2017, The oncologist.

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation.

M. Ghielmini, C. Sessa, M. D. de Jonge, 2003, European journal of cancer.

Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2004, European Journal of Cancer.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

J. Verweij, A. Sparreboom, R. Mathijssen, 2006, The oncologist.

Role of pharmacogenetics in irinotecan therapy.

J. Verweij, R. Mathijssen, M. D. de Jonge, 2006, Cancer letters.

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Clinical Cancer Research.

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

J. Verweij, A. Sparreboom, P. de Bruijn, 2004, British Journal of Cancer.

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

J. Verweij, A. Sparreboom, R. Mathijssen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

J. Verweij, M. D. de Jonge, J. Schellens, 1997, British Journal of Cancer.

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.

J. Verweij, H. Gelderblom, A. Sparreboom, 1999, Anti-cancer drugs.

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Anti-cancer drugs.

Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.

J. Verweij, A. Sparreboom, P. de Bruijn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Renal toxicities of chemotherapy.

J. Verweij, M. D. de Jonge, 2006, Seminars in Oncology.

Achievements and future of chemotherapy.

J. Verweij, M. D. de Jonge, M. Jonge, 2000, European journal of cancer.

Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT)

J. V. van Weert, M. D. de Jonge, E. Gort, 2019, BMC Palliative Care.

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

J. Machiels, R. Mathijssen, M. D. de Jonge, 2016, Cancer Chemotherapy and Pharmacology.

Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing

C. C. van der Rijt, J. V. van Weert, M. D. de Jonge, 2022, Cancers.

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

S. Sleijfer, J. Schellens, E. Voest, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.

R. Obach, J. Verweij, C. Twelves, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.

S. Sleijfer, A. Awada, M. D. de Jonge, 2022, European journal of cancer.

Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.

J. Verweij, M. D. de Jonge, 1996, Hematology.

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.

M. J. van den Bent, D. Lacombe, M. Campone, 2002, Annals of Oncology.

The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.

J. Verweij, A. Sparreboom, M. D. de Jonge, 1998, Cancer Treatment Reviews.

Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.

H. Groen, J. V. van Meerbeeck, M. D. de Jonge, 2008, Lung Cancer.

A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.

M. D. de Jonge, M. Forster, T. Busman, 2021, Future oncology.

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

F. J. Ramos, E. Wiemer, J. Baselga, 2013, Clinical Cancer Research.

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

M. Cotreau, J. Verweij, M. Thomeer, 2011, Clinical Cancer Research.

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

J. Verweij, M. D. de Jonge, E. Bone, 2010, British Journal of Cancer.

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

E. Wiemer, J. Verweij, H. Gelderblom, 2010, European journal of cancer.

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

G. Giaccone, D. Lacombe, E. Smit, 2004, European Journal of Cancer.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

S. Sleijfer, H. Horlings, E. Cuppen, 2017, Oncotarget.

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

M. Piccart, J. Verweij, A. Sparreboom, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule.

E. D. de Vries, J. Verweij, M. D. de Jonge, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multitarget tyrosine kinase inhibition: [and the winner is...].

J. Verweij, M. D. de Jonge, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

M. Ratain, P. LoRusso, D. Rasco, 2022, Investigational New Drugs.

Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future

J. Verweij, H. Gelderblom, A. Sparreboom, 1999, Investigational New Drugs.

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

H. Groen, T. Overbeck, Michael Thomas, 2020, The New England journal of medicine.

Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.

C. Rudin, M. Ratain, M. Sawyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).

C. Rudin, M. Ratain, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

M. D. de Jonge, C. V. van Herpen, M. Marotti, 2013, Anti-cancer drugs.

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

D. Lacombe, L. Paz-Ares, A. V. van Oosterom, 2004, Investigational New Drugs.

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

R. Salazar, R. Obach, J. Verweij, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.

J. Verweij, M. D. de Jonge, C. Puozzo, 2010, European Journal of Cancer.

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Y. Drew, S. Domchek, Young-Ae Park, 2019, Annals of Oncology.

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.

D. Lacombe, J. Verweij, C. Punt, 2006, European journal of cancer.

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.

R. Stupp, M. J. van den Bent, D. Lacombe, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

J. Baselga, D. Demanse, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

M. J. van den Bent, M. Zuraek, I. Aronchik, 2022, Neuro-oncology advances.

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, European Journal of Cancer.

Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aurora kinase inhibitors.

J. Verweij, M. D. de Jonge, M. D. de Jonge, 2010, Critical reviews in oncology/hematology.

Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.

T. Nijsten, M. D. de Jonge, Wil Bos, 2012, Archives of dermatology.

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material

Edwin Cuppen, Stef van Lieshout, Stefan Sleijfer, 2016, PloS one.

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

R. V. van Klaveren, J. V. van Meerbeeck, P. Baas, 2002, British Journal of Cancer.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

M. D. de Jonge, H. Arkenau, J. D. de Bono, 2015, Clinical Cancer Research.

A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

J. Verweij, I. Judson, S. Kaye, 2006, Clinical Cancer Research.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Jordi Rodon, Diana Birle, J. Baselga, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

A. Oberg, D. Visscher, A. Jager, 2019, Gynecologic oncology.

MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC: Topic: Medical Oncology

Dong-Wan Kim, M. Schuler, D. Hong, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.

J. Schellens, A. Le Cesne, M. D. de Jonge, 2017, European journal of cancer.

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

David C. Smith, M. Mclaughlin, J. Dobson, 2021, British Journal of Cancer.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

H. Hirte, L. Siu, Diane A van der Biessen, 2019, Targeted Oncology.

The epothilone dilemma.

J. Verweij, M. D. de Jonge, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

P. Ansell, J. Gietema, Diane A van der Biessen, 2018, Investigational New Drugs.

Topotecan lacks third space sequestration.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

J. Verweij, Sunil Sharma, M. D. de Jonge, 2011, Cancer Chemotherapy and Pharmacology.

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

H. Guchelaar, H. Gelderblom, R. Mathijssen, 2010, Investigational New Drugs.

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study

F. Saad, E. Posadas, M. D. de Jonge, 2020, Clinical Cancer Research.

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.

Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design

S. Sleijfer, J. Verweij, M. D. de Jonge, 2012, Molecular oncology.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

S. Sleijfer, J. Schellens, J. Beijnen, 2014, British Journal of Cancer.

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

M. Schuler, D. Hong, A. Delmonte, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.

J. Verweij, H. Gelderblom, A. Sparreboom, 2003, European journal of cancer.

Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: A systematic review.

J. V. van Weert, M. D. de Jonge, M. Lolkema, 2021, Cancer treatment reviews.

Evaluation of patient enrollment in oncology phase I clinical trials.

E. Wiemer, J. Verweij, B. van der Holt, 2013, The Oncologist.

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

P. Roepman, H. Gelderblom, H. Verheul, 2023, BMC Cancer.

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial

S. Jalkanen, P. Jaakkola, T. Lönnberg, 2020, Clinical Cancer Research.

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

J. Schellens, H. Verheul, A. Awada, 2020, British Journal of Cancer.

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.

J. Verweij, M. D. de Jonge, A. Mita, 2010, European journal of cancer.

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

J. Verweij, I. Judson, S. Kaye, 2004, British Journal of Cancer.

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

J. Verweij, H. Takano, A. Sparreboom, 2001, Anti-cancer drugs.

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

S. Sleijfer, R. Schilsky, E. Cuppen, 2019, Nature.

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

J. Verweij, C. Lamers, M. D. de Jonge, 2009, European Journal of Cancer.

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.

Riccardo Spinelli, J. Verweij, J. Nortier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?

J. Verweij, M. D. de Jonge, 2006, European Journal of Cancer.

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC).

H. Groen, E. Smit, R. Heist, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II

T. Gauler, A. Santoro, M. D. de Jonge, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gender-dependent pharmacokinetics of topotecan in adult patients

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Anti-cancer drugs.

Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Joon Sang Lee, Joonil Jung, Madelyn Light, 2016, Nature Communications.

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

H. Groen, E. D. de Vries, J. Verweij, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

J. Wanders, J. Verweij, A. Sparreboom, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

J. Verweij, M. D. de Jonge, J. D. de Bono, 2007, British Journal of Cancer.

Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data

M. J. van den Bent, M. D. de Jonge, J. Schouten, 2023, Cancers.

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

J. Koivunen, M. D. de Jonge, M. Karvonen, 2021, Annals of Oncology.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

J. Bloem, J. Verweij, J. Nortier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

S. Sleijfer, J. Schellens, C. Adessi, 2015, Clinical Cancer Research.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

H. Hirte, L. Siu, Diane A van der Biessen, 2019, Targeted Oncology.

Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.

R. Vernhout, K. Nackaerts, R. V. van Klaveren, 2010, Lung cancer.

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.

S. Domchek, Sang-We Kim, M. D. de Jonge, 2023, Lung cancer.

Self‐reported quality of life and hope in phase‐I trial participants: An observational prospective cohort study

R. Mathijssen, M. D. de Jonge, M. Lolkema, 2018, European journal of cancer care.

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.

D. Lacombe, C. Punt, S. Monfardini, 2004, European journal of cancer.

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Z. Wainberg, F. Ravandi, S. Dietrich, 2022, Blood.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

J. Blay, P. Wen, Y. Bang, 2023, Nature Medicine.

The use of oral cytotoxic and cytostatic drugs in cancer treatment.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2002, European journal of cancer.

QTc prolongation and/or oncology drug development: who's in danger?

J. Verweij, M. D. de Jonge, 2008, European journal of cancer.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

S. Sleijfer, E. Felip, J. Schellens, 2017, Clinical Cancer Research.

444OPHASE IB TRIAL TRIAL OF RG7116, A GLYCOENGINEERED MONOCLONAL ANTIBODY TARGETING HER3, IN COMBINATION WITH CETUXIMAB OR ERLOTINIB IN PATIENTS WITH ADVANCED/METASTATIC TUMORS OF EPITHELIAL CELL ORIGIN EXPRESSING HER3 PROTEIN.

S. Sleijfer, J. Schellens, C. Adessi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Danusertib, an aurora kinase inhibitor

J. Verweij, R. Mathijssen, M. D. de Jonge, 2012, Expert Opinion on Investigational Drugs.

Core values of patients with advanced cancer considering participation in an early-phase clinical trial: a qualitative study

J. V. van Weert, M. D. de Jonge, J. Hasselaar, 2022, Supportive Care in Cancer.

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials.

V. Budach, J. Debus, H. Verheul, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

J. Wanders, J. Verweij, M. D. de Jonge, 2005, Clinical Cancer Research.

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.

J. Verweij, M. D. de Jonge, P. Schöffski, 2011, European Journal of Cancer.

Chequerboard titrations: the influence of the composition of serial dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal concentration index.

M. D. de Jonge, J. Degener, K. Kerrebijn, 1987, The Journal of antimicrobial chemotherapy.

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

A. Tolcher, J. Verweij, K. Papadopoulos, 2011, British Journal of Cancer.

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

J. Verweij, H. Burger, M. D. de Jonge, 2010, British Journal of Cancer.

Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

S. Culine, J. Verweij, J. Bonneterre, 2002, Anti-cancer drugs.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

P. Ansell, J. Gietema, M. D. de Jonge, 2018, Investigational New Drugs.

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

M. D. de Jonge, T. Busman, A. Krivoshik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

H. Groen, E. Smit, R. Heist, 2019, Journal of Clinical Oncology.